| Studies | Guglielmelli et al. [17] | Jones et al. [18] | Steidl et al. [19] | Čokić et al. |
| MPN | PMF | PMF | PV | PV, ET, PMF |
| Purified from | PB-PMF BM-HC | PB-PMF BM-HC | BM-PMF BM-HC | PB-PV, ET, and PMF PB-HC |
| RNA | Pooled | Amplified 50 ng of total RNA | Individual | Amplified 300 ng of total RNA |
| Examined MPN patients | Mixed: de novo, treated/paused | Mixed: de novo, treated/paused | De novo | De novo |
| Number of patients | PMF, 3 × 5 HC, 3 × 5 | PMF, 8 HC, 6 | PV, 4 HC, 10 | PV, 7, ET, 9, PMF, 4, and HC, 8 |
| Microarray chips | Affymetrix HG-U133A GeneChip | Affymetrix HGU95Av2 chip | Atlas Clontech Human 1.2 I | Operon Human Genome 4.0 |
| Number of examined genes | 16.000 genes (22.238 probes) | 9.670 genes (12.625 probes) | 1.185 genes | 25.100 genes (35.035 probes) |
| JAK2V617F | Mixture of 8 mutated and 7 nonmutated | Not analyzed | Not analyzed | Separated according to mutant allele burden |
| Characterized genes | 174 | 95 (48 upregulated and 47 downregulated) | 107 | PV, 261, ET, 82, PMF, 94 |
|
|